AbCellera Investor Conference Presentation Deck

JPM HEALTHCARE CONFERENCE 2024 COPYRIGHT © ABCELLERA 7 OUR PIPELINE Advancing an internal pipeline of potential first-in-class and best-in-class assets is a top priority to drive growth. MOLECULE ABCL575 IND-ENABLING ABCL635 IND-ENABLING TARGET OX40L undisclosed GPCR or ion channel INDICATION atopic dermatitis undisclosed First two IND submissions anticipated in 2025. We intend to take additional first-in-class development candidates into IND-enabling studies in 2024 and 2025. $220M in non-dilutive funding from governments of Canada and British Columbia. THERAPEUTIC AREA immunology & inflammation metabolic & endocrine conditions POTENTIAL DIFFERENTIATION best in class first in class

View entire presentation